Literature DB >> 31821437

Screening for Abdominal Aortic Aneurysm: US Preventive Services Task Force Recommendation Statement.

Douglas K Owens1,2, Karina W Davidson3, Alex H Krist4,5, Michael J Barry6, Michael Cabana7, Aaron B Caughey8, Chyke A Doubeni9, John W Epling10, Martha Kubik11, C Seth Landefeld12, Carol M Mangione13, Lori Pbert14, Michael Silverstein15, Melissa A Simon16, Chien-Wen Tseng17,18, John B Wong19.   

Abstract

Importance: An abdominal aortic aneurysm (AAA) is typically defined as aortic enlargement with a diameter of 3.0 cm or larger. The prevalence of AAA has declined over the past 2 decades among screened men 65 years or older in various European countries. The current prevalence of AAA in the United States is unclear because of the low uptake of screening. Most AAAs are asymptomatic until they rupture. Although the risk for rupture varies greatly by aneurysm size, the associated risk for death with rupture is as high as 81%. Objective: To update its 2014 recommendation, the USPSTF commissioned a review of the evidence on the effectiveness of 1-time and repeated screening for AAA, the associated harms of screening, and the benefits and harms of available treatments for small AAAs (3.0-5.4 cm in diameter) identified through screening. Population: This recommendation applies to asymptomatic adults 50 years or older. However, the randomized trial evidence focuses almost entirely on men aged 65 to 75 years. Evidence Assessment: Based on a review of the evidence, the USPSTF concludes with moderate certainty that screening for AAA in men aged 65 to 75 years who have ever smoked is of moderate net benefit. The USPSTF concludes with moderate certainty that screening for AAA in men aged 65 to 75 years who have never smoked is of small net benefit. The USPSTF concludes that the evidence is insufficient to determine the net benefit of screening for AAA in women aged 65 to 75 years who have ever smoked or have a family history of AAA. The USPSTF concludes with moderate certainty that the harms of screening for AAA in women aged 65 to 75 years who have never smoked and have no family history of AAA outweigh the benefits. Recommendations: The USPSTF recommends 1-time screening for AAA with ultrasonography in men aged 65 to 75 years who have ever smoked. (B recommendation) The USPSTF recommends that clinicians selectively offer screening for AAA with ultrasonography in men aged 65 to 75 years who have never smoked rather than routinely screening all men in this group. (C recommendation) The USPSTF recommends against routine screening for AAA with ultrasonography in women who have never smoked and have no family history of AAA. (D recommendation) The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for AAA with ultrasonography in women aged 65 to 75 years who have ever smoked or have a family history of AAA. (I statement).

Entities:  

Year:  2019        PMID: 31821437     DOI: 10.1001/jama.2019.18928

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  42 in total

1.  Discovery of potential biomarkers for human atherosclerotic abdominal aortic aneurysm through untargeted metabolomics and transcriptomics.

Authors:  Lei Ji; Siliang Chen; Guangchao Gu; Wei Wang; Jinrui Ren; Fang Xu; Fangda Li; Jianqiang Wu; Dan Yang; Yuehong Zheng
Journal:  J Zhejiang Univ Sci B       Date:  2021 Sept 15       Impact factor: 3.066

2.  A Novel Mechanism Underlying Inflammatory Smooth Muscle Phenotype in Abdominal Aortic Aneurysm.

Authors:  Dunpeng Cai; Chenming Sun; Gui Zhang; Xingyi Que; Ken Fujise; Neal L Weintraub; Shi-You Chen
Journal:  Circ Res       Date:  2021-09-23       Impact factor: 17.367

3.  Kallikrein-1 Blockade Inhibits Aortic Expansion in a Mouse Model and Reduces Prostaglandin E2 Secretion From Human Aortic Aneurysm Explants.

Authors:  Corey S Moran; Erik Biros; Smriti M Krishna; Susan K Morton; Daniel J Sexton; Jonathan Golledge
Journal:  J Am Heart Assoc       Date:  2021-02-18       Impact factor: 5.501

4.  Cost-effectiveness of a population-based AAA screening program for men over 65 years old in Iran.

Authors:  Rajabali Daroudi; Omid Shafe; Jamal Moosavi; Javad Salimi; Yahya Bayazidi; Mohammad Reza Zafarghandi; Majid Maleki; Majid Moini; Pezhman Farshidmehr; Parham Sadeghipour
Journal:  Cost Eff Resour Alloc       Date:  2021-05-13

5.  Appraisal of transthoracic echocardiography for opportunistic screening of abdominal aortic aneurysm.

Authors:  Ozlem Ozcan Celebi; Savas Celebi; Berkten Berkalp
Journal:  Medicine (Baltimore)       Date:  2021-06-04       Impact factor: 1.817

6.  Body Mass Index and Mortality From Aortic Aneurysm and Dissection.

Authors:  Midori Takada; Kazumasa Yamagishi; Akiko Tamakoshi; Hiroyasu Iso
Journal:  J Atheroscler Thromb       Date:  2020-07-28       Impact factor: 4.928

7.  Sex-specific criteria for repair should be utilized in patients undergoing aortic aneurysm repair.

Authors:  Priya B Patel; Livia E V M De Guerre; Christina L Marcaccio; Kirsten D Dansey; Chun Li; Ruby Lo; Virendra I Patel; Marc L Schermerhorn
Journal:  J Vasc Surg       Date:  2021-09-08       Impact factor: 4.268

8.  Lipoprotein(a) levels and risk of abdominal aortic aneurysm in the Women's Health Initiative.

Authors:  Elizabeth L Chou; Mary Pettinger; Bernhard Haring; Matthew W Mell; Mark A Hlatky; Jean Wactawski-Wende; Matthew A Allison; Robert A Wild; Aladdin H Shadyab; Robert B Wallace; Linda G Snetselaar; Matthew J Eagleton; Mark F Conrad; Simin Liu
Journal:  J Vasc Surg       Date:  2020-08-31       Impact factor: 4.268

9.  Global Burden of Aortic Aneurysm and Attributable Risk Factors from 1990 to 2017.

Authors:  Linyan Wei; Xiang Bu; Xiqiang Wang; Jing Liu; Aiqun Ma; Tingzhong Wang
Journal:  Glob Heart       Date:  2021-05-04

Review 10.  Circular RNA Expression: Its Potential Regulation and Function in Abdominal Aortic Aneurysms.

Authors:  Yanshuo Han; Hao Zhang; Ce Bian; Chen Chen; Simei Tu; Jiahui Guo; Yihao Wu; Dittmar Böckler; Jian Zhang
Journal:  Oxid Med Cell Longev       Date:  2021-06-29       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.